Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
The immediate release d-MPH treatment is indicated for ADHD patients at least 6 years old.
The US Food and Drug Administration (FDA) has approved serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) (AZSTARYS) capsules for the treatment of attention deficit/hyperactivity disorder (ADHD).
The approval, awarded for KemPharm, is for the treatment to be used as a once-daily oral capsule in patients at least 6 years old, co-formulated in a way that results in the immediate release of d-MPH.
The treatment was developed to meet some of the unmet needs of ADHD patients with the most widely-prescribed methylphenidate ADHD, including earlier onset of action and longer duration of therapy. The treatment is also designed to avoid unnecessary spikes in d-MPH concentrations that are commonly associated with adverse events.
The treatment is expected to be available in the US during the third quarter of 2021.
“The FDA approval of the AZSTARYS NDA is a transformational event for KemPharm and, we believe, an important advancement in the treatment of ADHD,” Travis C. Mickle, PhD, President and CEO of KemPharm, said in a statement. “Today’s approval highlights both the value potential of SDX, our prodrug of d-MPH, and the ability of our LAT platform technology to develop new prodrugs of approved medications that improve one or more of the attributes of the parent drug. We look forward to continuing our support of Corium as they forge ahead with the commercial launch of AZSTARYS.”
In December, representatives from KenPharm met with the FDA in a late-cycle communication meeting to discuss the drug, formerly called KP415. In the meeting, the agency did not raise any substantive issues related to the safety and efficacy of the treatment.